Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. reported that Chief Business Officer Behrad Derakhshan received a grant of 100,000 stock options to purchase common stock. This amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date. The options vest in 1/48 monthly installments beginning September 12, 2026, contingent on continued service, and expire on August 12, 2036. Following this grant, Derakhshan holds 100,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Derakhshan Behrad
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 100,000 shares (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
Options Granted: 100,000 shares
Exercise Price: $43.56 per share
Underlying Shares: 100,000 shares
+4 more
7 metrics
Options Granted
100,000 shares
Stock Option (Right to Buy) granted to Chief Business Officer
Exercise Price
$43.56 per share
Corrected option exercise price reflecting fair market value on grant date
Underlying Shares
100,000 shares
Common Stock underlying the reported stock option
Post-transaction Derivative Holdings
100,000 shares
Total derivative securities held directly after the grant
Vesting Rate
1/48 per month
Monthly vesting installments beginning September 12, 2026
Vesting Start Date
September 12, 2026
First vesting date for the stock option grant
Expiration Date
August 12, 2036
Option expiration for the stock option (right to buy)
Key Terms
Stock Option (Right to Buy), exercise price, vesting, derivative securities, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"corrects the exercise price of the reported option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares subject to the option vest each month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative securities financial
"total_shares_following_transaction: 100000.0000 derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
fair market value financial
"reflects the fair market value of the underlying security"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
FAQ
What insider equity award was reported for Edgewise Therapeutics (EWTX)?
Edgewise Therapeutics reported a grant of 100,000 stock options to Chief Business Officer Behrad Derakhshan. These options relate to the company’s common stock and represent a new equity-based compensation award.
What is the corrected exercise price of the EWTX stock options in this Form 4/A?
The amendment corrects the option exercise price to $43.56 per share. The original filing mistakenly showed $0.00 due to a clerical error; $43.56 reflects fair market value on the grant date.
How do the Edgewise Therapeutics (EWTX) options granted to Derakhshan vest?
The options vest in 1/48th of the shares each month starting September 12, 2026. Vesting is conditioned on Derakhshan continuing as a service provider through each monthly vesting date.
When do the reported Edgewise Therapeutics (EWTX) stock options expire?
The stock options expire on August 12, 2036. If unexercised by that date, the right to purchase the underlying common shares lapses according to the award’s stated expiration.
How many Edgewise Therapeutics (EWTX) derivative securities does Derakhshan hold after this grant?
After the reported grant, Derakhshan directly holds 100,000 derivative securities in the form of stock options. This figure reflects the total options position reported following the transaction.
Was the Edgewise Therapeutics (EWTX) option transaction under a Rule 10b5-1 plan?
The filing indicates the Rule 10b5-1 checkbox is not affirmatively marked for this transaction. There is no footnote stating that the grant occurred under a pre-arranged 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
